An observational study in Critical Illness and Sepsis, Severe, sponsored by Children's Hospital of Fudan University. Withdrawn. Open to participants aged 29 Days to 18 Years. Per ClinicalTrials.gov, last updated 2022-06-15.
Sponsored by Children's Hospital of Fudan University · Observational
In severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe secondary hospital-acquired infections. However, the role of IL-1β and its receptor antagonists in patients with severe sepsis and septic shock is discussed controversially. To date, the efficacy and safety of IL-1β and its receptor antagonists in children with severe infection is not fully evaluated.
The investigators intend to enroll all children who were hospitalized in pediatric intensive care unit of Children's Hospital of Fudan University from January 2022 to December 2023. Children with a PICU length of day less than 48h will be excluded. Patients who met the inclusion criteria will be divided into trial group and control group. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record.
1,894 studies on the registry are indexed under Sepsis; 458 are open to participants now.
Browse Sepsis studies →Children's Hospital of Fudan University is the lead sponsor of 262 studies on the registry; 92 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All children hospitalized in PICU of Children's Hospital of Fudan University from January 2022 to December 2023
Exclusion Criteria:
anakinra canakinumab
conventional treatment
survival rate
The death rate of children in 28 days after their discharged from PICU
Time frame: within 28 days after they discharged from PICU
length of stay in PICU
Time from PICU admission to discharge
Time frame: within 28 days after they discharged from PICU
No study locations are listed for this record.
This study is withdrawn, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital of Fudan University